JAZZ241220P115000
- 0.68
- 0.000.00%
Jazz Pharmaceuticals Newsroom
Jazz Pharmaceuticals (JAZZ) Is Making Sweet Music With a Diverse Portfolio
Why Jazz Pharmaceuticals (JAZZ) Is One of the Most Undervalued Pot Stocks to Buy?
RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
Express News | Jazz Pharmaceuticals PLC - Revolving Credit Facility Maturity Date Extended to November 26, 2029
Express News | Jazz Pharmaceuticals PLC - Amends Credit Agreement to Increase Commitments
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $160 to $207
Jazz Pharmaceuticals Price Target Lowered to $163 From $166 at Piper Sandler
Jazz Pharmaceuticals Insiders Sold US$1.7m Of Shares Suggesting Hesitancy
Barclays Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
FDA Roundup: November 22, 2024
Jazz Pharmaceuticals: Promising Growth Potential With Robust Pipeline and Undervalued Market Position
Express News | FDA Grants Accelerated Approval to Zanidatamab-Hrii for Previously Treated Unresectable or Metastatic Her2-Positive Biliary Tract Cancer
Express News | Jazz Pharmaceuticals PLC : Jefferies Raises Target Price to $160 From $158
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK
Sector Update: Health Care Stocks Rise Pre-Bell Thursday
Positive Outlook for Jazz Pharmaceuticals Following Ziihera Approval
Jazz Pharmaceuticals Analyst Ratings
Sector Update: Health Care
Nvidia Earnings in Focus as US Equity Futures Post Narrow Gains Pre-Bell